Navigation Links
Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
Date:3/4/2013

Norwood, MA (PRWEB) March 04, 2013

Infinata’s BioPharm Insight released its Licensing League Tables Report for 4Q12 and YE12 to subscribers in mid-February. This report provides insight needed to evaluate market opportunities, market values and trends as well as competitive strategies.

The total volume and disclosed value of licensing agreements involving pharmaceutical products picked up in 4Q12. The quarter has seen 110 agreements with an aggregate disclosed value of USD 6,813m. That is an increase of 36% in volume and 42% in value from 3Q12, in which 81 agreements worth USD 4,787m were announced. The Antibody Program agreement between Menarini Group and Oxford BioTherapeutics was the largest deal in 4Q12, potentially valued at USD 1,035m.

Topping the charts in 4Q, legal advisor Wilson, Sonsini Goodrich & Rositi led the volume table having advised on eight transactions valued at USD 551m. While WilmerHale led the global value table for 4Q, having advised on six drug licensing agreements valued at USD 685m.

WilmerHale also led the global and North American volume tables for YE12 with 27 transactions valued at USD 1,283m, while tying with Cooley for the European volume tables, both having advised on eight transactions. Cooley also led the global and North American value tables for YE12 with 26 transactions valued at USD 4,280m and 25 transactions valued at USD 4,272m, respectively. Covington & Burling took the top spot for the European value table for YE12 having advised on seven agreements valued at USD 3,765m.

Access all of BioPharm Insight’s reports by starting a free trial today.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com. Follow BioPharm Insight on LinkedIn and Twitter.

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10476962.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
2. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
3. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
4. PDL BioPharma to Present at Two Upcoming Investor Conferences
5. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
8. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
9. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
10. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
11. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):